TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11908533

Group type: EXPERIMENTAL
Intervention: Consistently negative feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Changing feedback from positive to negative
Number of subjects: 0
Study: 10084489

Group type: EXPERIMENTAL
Intervention: Group A (left chest tube inserted from the midline, subxyphoid)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Group B (tube placed in the sixth intercostal space at the anterior axillary line)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 30

Group type: COMPARATOR
Intervention: Group B
Number of subjects: 30
Study: 7555622

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ), titrated to 4-12 micrograms/ml
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 2208421

Group type: EXPERIMENTAL
Intervention: Injection of Scutellaria compound
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous piperacillin sodium
Number of subjects: 60
Study: 6109147

Group type: EXPERIMENTAL
Intervention: Real ECT
Number of subjects: 70

Group type: COMPARATOR
Intervention: Simulated ECT
Number of subjects: 70
Study: 30081009

Group type: EXPERIMENTAL
Intervention: Maxillomandibular advancement (MMA)
Number of subjects: 30
Study: 28954501

Group type: EXPERIMENTAL
Intervention: Three-week early cardiac rehabilitation (CR) exercise training
Number of subjects: 65
Study: 25713429

Group type: EXPERIMENTAL
Intervention: Psychosocial telephone counseling (PTC)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 204
Study: 24517055

Group type: EXPERIMENTAL
Intervention: Bushen Zhuanggu Quhan Decoction + WM placebos (Group A)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Bushen Zhuanggu Qinghua Decoction + WM placebos (Group B)
Number of subjects: 96

Group type: COMPARATOR
Intervention: SASP + TCM placebos (Group C)
Number of subjects: 96

Group type: COMPARATOR
Intervention: SASP + TCM placebos (Group D)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: TCM treatment group (combined A and B)
Number of subjects: 96
Study: 21639808

Group type: EXPERIMENTAL
Intervention: vemurafenib (960 mg orally twice daily)
Number of subjects: 675

Group type: COMPARATOR
Intervention: dacarbazine (1000 mg/m² intravenously every 3 weeks)
Number of subjects: 675

Group type: EXPERIMENTAL
Intervention: vemurafenib
Number of subjects: 675

Group type: COMPARATOR
Intervention: dacarbazine
Number of subjects: 675
Study: 19853906

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Liraglutide 2.4 mg
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg
Number of subjects: 564

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Liraglutide (all doses)
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8-3.0 mg
Number of subjects: 564
Study: 16419071

Group type: COMPARATOR
Intervention: VAD alone
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: valspodar/VAD
Number of subjects: 94
Study: 12727150

Group type: EXPERIMENTAL
Intervention: Early revascularization <18 hours since onset of shock
Number of subjects: 865

Group type: COMPARATOR
Intervention: Late or no revascularization
Number of subjects: 865
Study: 10965733

Group type: EXPERIMENTAL
Intervention: Propofol 1% (10 mg/ml)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Propofol 2% (20 mg/ml)
Number of subjects: 73
Study: 8911979

Group type: EXPERIMENTAL
Intervention: Glimepiride at a daily dose of 1-6 mg for 3 months in NIDDM patients with kidney disease
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Glimepiride in patients with liver disease
Number of subjects: 42
Study: 1507042

Group type: COMPARATOR
Intervention: Root planed only (Group 2)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Laser treated only using 1.25 W of energy (Group 3)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Laser treated only using 1.50 W of energy (Group 4)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Laser treated with 1.25 W of energy followed by root planing (Group 5)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Laser treated with 1.50 W of energy followed by root planing (Group 6)
Number of subjects: 18
Study: 6509875

Group type: EXPERIMENTAL
Intervention: 0.9% sodium chloride injection alone
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Heparin 10 units/ml in 0.9% sodium chloride injection
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Heparin 100 units/ml in 0.9% sodium chloride injection
Number of subjects: 412
Study: 31385180

Group type: EXPERIMENTAL
Intervention: SRL-MPA-S
Number of subjects: 15008

Group type: EXPERIMENTAL
Intervention: SRL-TAC-S
Number of subjects: 15008

Group type: EXPERIMENTAL
Intervention: SRL-CSA-S
Number of subjects: 15008

Group type: COMPARATOR
Intervention: TAC-MPA-S
Number of subjects: 15008
Study: 28371815

Group type: EXPERIMENTAL
Intervention: FG-4592 low-dose (1.1-1.75 mg/kg)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: FG-4592 high-dose (1.50-2.25 mg/kg)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: FG-4592 low-dose (1.1-1.8 mg/kg)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: FG-4592 medium-dose (1.5-2.3 mg/kg)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: FG-4592 high-dose (1.7-2.3 mg/kg)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Epoetin alfa
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: FG-4592 (all doses)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: FG-4592 high-dose
Number of subjects: 178
Study: 25732264

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus pemetrexed (GP)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Gemcitabine plus carboplatin (GC)
Number of subjects: 94
Study: 23512113

Group type: EXPERIMENTAL
Intervention: Trans-obturator polypropylene mesh
Number of subjects: 147

Group type: COMPARATOR
Intervention: Anterior colporrhaphy
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 147
Study: 21511749

Group type: EXPERIMENTAL
Intervention: ICRU point doses in Group A (n=50)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Statistical validation in Group B (n=100)
Number of subjects: 150
Study: 20112486

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 0
Study: 16918716

Group type: EXPERIMENTAL
Intervention: L-arginine (3 g daily)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 14639479

Group type: EXPERIMENTAL
Intervention: Resistance training in addition to aerobic training (n=9); trained on 12 resistance machines, performing three sets of 8-12 repetitions at 32-64% of their one-repetition maximum (1-RM) lifts
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control/aerobic training (n=8)
Number of subjects: 17
Study: 11605012

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (including anthracycline and non-anthracycline based regimens)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doxorubicin and cyclophosphamide (AC)
Number of subjects: 0
Study: 9469687

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (Atrovent) nebulizer solution with BAC and EDTA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Albuterol nebulizer solution with BAC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EDTA in nebulizer solutions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preservative-free bronchodilator nebulizer solutions
Number of subjects: 0
Study: 7927550

Group type: EXPERIMENTAL
Intervention: Cortisol estimation from cord artery, cord vein at birth and from peripheral vein at 6 h of age.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Maternal venous blood cortisol estimation at birth.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cord blood pH measurement at birth.
Number of subjects: 60
Study: 2556910

Group type: EXPERIMENTAL
Intervention: very-high-fiber (VHF) cereal
Number of subjects: 14

Group type: COMPARATOR
Intervention: very-low-fiber (VLF) cereal
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: high-fiber cereals
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: higher-fiber cereals
Number of subjects: 14
Study: 125068

Group type: EXPERIMENTAL
Intervention: Topical application of 1.5% aqueous solution of 6-aminonicotinamide for four weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Solvent alone (control)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Topically applied thionicotinamide
Number of subjects: 34
Study: 30676219

Group type: EXPERIMENTAL
Intervention: Multimodal exercise program performed barefoot
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Multimodal exercise program performed shod
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group (no physical exercise)
Number of subjects: 3
Study: 28987873

Group type: EXPERIMENTAL
Intervention: Patients with knee osteoarthritis at 5 years after anterior cruciate ligament reconstruction
Number of subjects: 19

Group type: COMPARATOR
Intervention: Patients without knee osteoarthritis at 5 years after anterior cruciate ligament reconstruction
Number of subjects: 19
Study: 24895097

Group type: EXPERIMENTAL
Intervention: Intensive lowering of LDL-cholesterol and blood pressure
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard therapy indicated by current guidelines
Number of subjects: 100
Study: 23937923

Group type: EXPERIMENTAL
Intervention: 10mg intravenous dexamethasone intraoperatively
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 24-hour postoperative dose of 10mg intravenous dexamethasone
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no dexamethasone)
Number of subjects: 120
Study: 21504256

Group type: EXPERIMENTAL
Intervention: IVR system call 7 days before the procedure
Number of subjects: 3610

Group type: EXPERIMENTAL
Intervention: IVR system call 3 days before the procedure
Number of subjects: 3610

Group type: COMPARATOR
Intervention: Nurse phone call 7 days before the procedure
Number of subjects: 3610
Study: 18650033

Group type: EXPERIMENTAL
Intervention: Open label sustained-release bupropion (300 mg/day) with gain-framed messages
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Open label sustained-release bupropion (300 mg/day) with loss-framed messages
Number of subjects: 207

Group type: COMPARATOR
Intervention: Expired CO
Number of subjects: 207

Group type: COMPARATOR
Intervention: Plasma cotinine
Number of subjects: 207
Study: 16858180

Group type: EXPERIMENTAL
Intervention: Iloprost (intra-arterial, intraoperative bolus of 3000 ng, plus intravenous infusion of 0.5-2.0 ng/kg/min for 6 hours/day for 4-7 days following surgery)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Iloprost
Number of subjects: 300
Study: 12460133

Group type: EXPERIMENTAL
Intervention: 9-session cognitive behavioral treatment (CBT) with motivational enhancement therapy (MET) and case management (CM) components
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: 2-session MET intervention
Number of subjects: 450

Group type: COMPARATOR
Intervention: Delayed treatment control (DTC)
Number of subjects: 450
Study: 10466460

Group type: EXPERIMENTAL
Intervention: Bendrofluazide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pulse pressure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mean blood pressure
Number of subjects: 0
Study: 8576309

Group type: EXPERIMENTAL
Intervention: Synthetic HEV peptides (EH174 from ORF-1, EH286 from ORF-2, EH362 from ORF-3) used in peptide-based ELISA test kits.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peptide-based ELISA test kits using a set of 3 synthetic HEV peptides as coating antigens.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Seroepidemiological survey.
Number of subjects: 0
Study: 2024858

Group type: COMPARATOR
Intervention: Standard treatment (high-dose steroid therapy plus cyclophosphamide therapy for 8 weeks)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Plasmapheresis treatment (12 plasmapheresis procedures during the first 4 weeks)
Number of subjects: 86
Study: 7440855

Group type: EXPERIMENTAL
Intervention: Flunisolide aerosol
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 6724070

Group type: EXPERIMENTAL
Intervention: Acyclovir cream
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 52

Group type: COMPARATOR
Intervention: Liquid nitrogen
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Liquid nitrogen (subsequent treatment)
Number of subjects: 52
Study: 30962877

Group type: EXPERIMENTAL
Intervention: Treatment as usual plus manual therapy (5 sessions, 30 min each)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Treatment as usual plus manual therapy
Number of subjects: 64
Study: 29129455

Group type: COMPARATOR
Intervention: Type 2 Diabetes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postprandial state
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fasting AC16:0
Number of subjects: 0
Study: 26755593

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted trivalent inactivated influenza vaccine (ATIV)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Trivalent inactivated influenza vaccine (TIV)
Number of subjects: 90
Study: 23774008

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for childhood OCD, 12-session course
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for childhood OCD
Number of subjects: 40
Study: 22926289

Group type: EXPERIMENTAL
Intervention: Naftopidil 25 mg/day
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Naftopidil 25 mg/day plus tolterodine 2 mg (twice a day)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Tolterodine 2 mg (twice a day)
Number of subjects: 76
Study: 20116107

Group type: EXPERIMENTAL
Intervention: Positive emotional messages with more vocal information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fearful emotional messages
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive emotional messages with intense vocal tone
Number of subjects: 0
Study: 17661956

Group type: EXPERIMENTAL
Intervention: Tai chi intervention (16-week program of community-based tai chi classes of 1 hour duration per week)
Number of subjects: 702

Group type: COMPARATOR
Intervention: Control group (waiting list control)
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Tai chi intervention
Number of subjects: 702
Study: 16238864

Group type: EXPERIMENTAL
Intervention: Brief research-based leaflet-like intervention promoting fruit and vegetable consumption
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 12453954

Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study: 10521751

Group type: EXPERIMENTAL
Intervention: Morning meal administered at 7 AM after a fast of ≥5 hours
Number of subjects: 30

Group type: COMPARATOR
Intervention: Evening meal administered at 9 PM after a fast of ≥5 hours
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Morning meal
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Overweight patients
Number of subjects: 30
Study: 8729258

Group type: EXPERIMENTAL
Intervention: Experimental product based on raw wheat flour subjected to enzymatic hydrolysis
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control product based on extruded flours and milk protein
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Experimental product
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control product
Number of subjects: 35
Study: 1906413

Group type: EXPERIMENTAL
Intervention: Misoprostol (400 micrograms/day)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: No prevention (control)
Number of subjects: 1000
Study: 7195642

Group type: EXPERIMENTAL
Intervention: tranexamic acid (AMCA)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control
Number of subjects: 41
Study: 31022892

Group type: EXPERIMENTAL
Intervention: Iron folate group (60 mg elemental iron and folate)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Iron, vitamin A and folate group
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Vitamin A group (15,000 IU of vitamin)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Folate group (2.5 mg of folate)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 402
Study: 30267399

Group type: EXPERIMENTAL
Intervention: 153 Sm-EDTMP
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 177 Lu-EDTMP
Number of subjects: 50
Study: 26914455

Group type: EXPERIMENTAL
Intervention: Veratric acid (VA) cream applied topically; specific dosage and duration not mentioned.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified; no control intervention mentioned.
Number of subjects: 0
Study: 25200338

Group type: EXPERIMENTAL
Intervention: Derivation set
Number of subjects: 3413

Group type: EXPERIMENTAL
Intervention: Validation set
Number of subjects: 3413
Study: 22706571

Group type: COMPARATOR
Intervention: IV iron sucrose (IS)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: IV iron sucrose co-administered with IV Vitamin C (IS + C)
Number of subjects: 13
Study: 20130877

Group type: EXPERIMENTAL
Intervention: Docetaxel and cisplatin (75 mg/m2 every 3 weeks)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Docetaxel and cisplatin with radiation therapy (RT; 45 Gy)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Docetaxel and cisplatin (arm A)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Docetaxel and cisplatin with RT (arm B)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: ERCC1 positive tumors
Number of subjects: 147
Study: 18040014

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) at a mean dose of 2000 mg/day
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) at a mean dose of 564 mg/day
Number of subjects: 28

Group type: COMPARATOR
Intervention: Non-drug
Number of subjects: 28
Study: 15656813

Group type: EXPERIMENTAL
Intervention: Once-daily use of topical corticosteroids
Number of subjects: 10

Group type: COMPARATOR
Intervention: More frequent use of topical corticosteroids
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Twice-daily treatment with potent topical corticosteroids
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Three times daily use of very potent topical corticosteroids
Number of subjects: 10
Study: 12198015

Group type: EXPERIMENTAL
Intervention: High fiber, low fat meal
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Low fiber, high fat meal
Number of subjects: 15

Group type: COMPARATOR
Intervention: Low fiber, low fat meal
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High-fat, low-fiber meal
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Low-fiber, low-fat meal
Number of subjects: 15
Study: 10608543

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) (Pentaspan)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Gelatine (Gelofusine)
Number of subjects: 45
Study: 7491877

Group type: EXPERIMENTAL
Intervention: Dexfenfluramine (30 mg)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Fluoxetine (40 mg)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 1851068

Group type: EXPERIMENTAL
Intervention: Baseline skin microcirculation (laser Doppler flux)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Baseline plasma noradrenaline concentration
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alpha 2‐adrenoceptor density
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alpha 2‐adrenoceptor density/beta 2‐adrenoceptor density ratio
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Mental arithmetic test
Number of subjects: 24

Group type: COMPARATOR
Intervention: Finger-cooling test
Number of subjects: 24
Study: 6809627

Group type: EXPERIMENTAL
Intervention: 10 micrograms of Neisseria meningitidis group Y and group W135 polysaccharide vaccine
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 25 micrograms of Neisseria meningitidis group Y and group W135 polysaccharide vaccine
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 50 micrograms of Neisseria meningitidis group Y and group W135 polysaccharide vaccine
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 100 micrograms of Neisseria meningitidis group Y and group W135 polysaccharide vaccine
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 25 micrograms in a 20-microliter/microgram volume
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Preexisting serum bactericidal activity (greater than 4 log2)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: High preexisting serum bactericidal titers
Number of subjects: 64
Study: 31571526

Group type: EXPERIMENTAL
Intervention: Dynamic treatment regimen for increasing motivation to attend treatments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard two-arm randomized trial
Number of subjects: 0
Study: 29523170

Group type: EXPERIMENTAL
Intervention: Regular feedback about activity levels via Smart watch
Number of subjects: 0

Group type: COMPARATOR
Intervention: No feedback while wearing the Smart watch
Number of subjects: 0
Study: 26291817

Group type: EXPERIMENTAL
Intervention: 300 mg intravaginal progesterone
Number of subjects: 200

Group type: COMPARATOR
Intervention: 600 mg intravaginal progesterone
Number of subjects: 200
Study: 25261353

Group type: EXPERIMENTAL
Intervention: Random Group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Definite Group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0